Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.
Journal: Science signaling
Published: November 25, 2025
Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay.
Journal: STAR protocols
Published: April 29, 2024
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.
Journal: bioRxiv : the preprint server for biology
Published: December 18, 2023
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 16, 2023
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies.
Journal: iScience
Published: July 13, 2023
SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis.
Journal: bioRxiv : the preprint server for biology
Published: July 10, 2023
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies.
Journal: bioRxiv : the preprint server for biology
Published: February 07, 2023
177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 01, 2020
Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).
Journal: Frontiers in oncology
Published: July 03, 2019
The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.
Journal: Journal of molecular endocrinology
Published: June 28, 2019
Last Updated: 09/26/2026